Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

References for PMC Articles for PubMed (Select 11005867)

1.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM.

Antimicrob Agents Chemother. 2000 Apr;44(4):920-8.

2.

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.

Hertogs K, Bloor S, De Vroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Stürmer M, Alcorn T, Wegner S, van Houtte M, Miller V, Larder BA.

Antimicrob Agents Chemother. 2000 Mar;44(3):568-73.

3.

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD.

JAMA. 2000 Jan 12;283(2):229-34.

PMID:
10634339
4.

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F.

JAMA. 2000 Jan 12;283(2):205-11. Erratum in: JAMA 2000 Sep 27;284(12):1518.

PMID:
10634336
5.

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD.

Nat Med. 2000 Jan;6(1):82-5.

PMID:
10613829
6.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
7.

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA.

AIDS. 1999 Dec 3;13(17):2349-59.

PMID:
10597776
8.

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Günthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK.

J Virol. 1999 Nov;73(11):9404-12.

9.

Ongoing HIV dissemination during HAART.

Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi I, Jankelevich S, Yarchoan R, Boon J, de Wolf F, Lange JM, Goudsmit J, Dimitrov DS, Paul WE.

Nat Med. 1999 Oct;5(10):1099-104. No abstract available.

PMID:
10502799
10.

Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Martinez-Picado J, Sutton L, De Pasquale MP, Savara AV, D'Aquila RT.

J Clin Microbiol. 1999 Sep;37(9):2943-51.

11.

Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.

Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L.

J Infect Dis. 1999 Sep;180(3):850-3.

12.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

13.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.

N Engl J Med. 1999 May 27;340(21):1605-13.

14.

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF.

Nat Med. 1999 May;5(5):512-7.

PMID:
10229227
15.

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database.

Shafer RW, Stevenson D, Chan B.

Nucleic Acids Res. 1999 Jan 1;27(1):348-52.

16.

Drug concentration heterogeneity facilitates the evolution of drug resistance.

Kepler TB, Perelson AS.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11514-9.

17.

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A.

J Virol. 1998 Sep;72(9):7532-41.

18.

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD.

JAMA. 1998 Jun 24;279(24):1984-91. Review.

PMID:
9643863
20.

Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD.

J Virol. 1998 Mar;72(3):2422-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk